This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2027 Remove Diabetes Remove Pharmaceutical Companies Related Topics
Pharmaceutical Companies Packaging Biosimilars Compounding Labelling More Related Topics >
article thumbnail

Eli Lilly plans to invest $450m at production site in Research Triangle Park

Pharmafile

JANUARY 25, 2023

US-based pharmaceutical company, Eli Lilly and Company, has announced plans to invest $450m in its manufacturing facilities at Research Triangle Park in North Carolina, US. The facility is expected to become operational in 2027 and will create over 100 new jobs for manufacturing personnel. read more

Packaging 52
Packaging Diabetes Pharmaceutical Companies Pharmaceutical Companies 52
article thumbnail

T2D market growth driven by novel GLP-1RAs and once-weekly basal insulin therapies

Pharmaceutical Technology

JANUARY 10, 2023

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

Biosimilars 52
Biosimilars Labelling Diabetes Compounding 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 33,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024